Roche Holdings completes acquisition of 89bio and delists company from Nasdaq
PositiveFinancial Markets

Roche Holdings has successfully completed its acquisition of 89bio, a move that not only strengthens Roche's portfolio in the biopharmaceutical sector but also marks the delisting of 89bio from Nasdaq. This acquisition is significant as it reflects Roche's commitment to expanding its innovative therapies and enhancing its market position, which could lead to improved patient outcomes and growth opportunities for the company.
— Curated by the World Pulse Now AI Editorial System







